Bevacizumab (anti-VEGF)

Catalog No.A2006 Synonyms: rhuMab VEGF, Avastin

For research use only.
Not for use in humans.

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Bevacizumab (anti-VEGF)

Selleck's Bevacizumab (anti-VEGF) has been cited by 20 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.
Targets
VEGFR2 [4] VEGF-A [4] VEGF [1]
In vitro

Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.[1]

In vivo

The combinational treatment of AAV9-LECT2-shRNA and bevacizumab significantly improves the therapeutic effects on liver fibrosis.[2]

Protocol (from reference)

Cell Research:
  • Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.

Animal Research:
  • Animal Models: Male C57BL/6J mice of CCl4-induced fibrosis model
    Dosages: 2 mg/kg
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/34940991/
     

Product Details

CAS No. 216974-75-3
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

Tags: buy Bevacizumab (anti-VEGF) | Bevacizumab (anti-VEGF) supplier | purchase Bevacizumab (anti-VEGF) | Bevacizumab (anti-VEGF) cost | Bevacizumab (anti-VEGF) manufacturer | order Bevacizumab (anti-VEGF) | Bevacizumab (anti-VEGF) distributor